QuantoBio

Beijing QuantoBio Biotechnology Co. Ltd. is a biotechnology firm specializing in high-quality reagents and solutions for immunology research and clinical diagnostics. Founded in September 2009 in Beijing, China, by a team of returning entrepreneurs in partnership with Morningside Ventures, Vcanland, and TusPark Ventures, the company has established itself as a key supplier in its field.

QuantoBio operates across four main technology platforms: Molecular Biology, Molecular Immunology, Cell Immunology, and Protein Engineering. The company develops and provides a range of products, including antibodies, reagents for flow cytometry, molecular diagnostics, and protein immunology products focused on cancer and infectious diseases. Its offerings cater to clinical hospitals, third-party medical institutions, CDCs, and research laboratories. The business model involves the development, production, marketing, and servicing of clinical diagnostic products, efficacy assessment tools, and health warning products, with revenue generated from product sales, including OEM services and bulk materials for industrial partners.

The firm has a history of participating in national research and development projects and holds numerous national invention patents. After several venture funding rounds, the company went through an IPO in January 2016 and a post-IPO equity round in September 2017. Notable achievements include being named one of the "Zhongguancun Top 10 New Enterprises" and among the "Delloitte China Top 50 High-tech Fast-develop companies" in 2013.

Keywords: immunology reagents, clinical diagnostics, biotechnology, molecular diagnostics, flow cytometry, antibodies, protein engineering, cancer research, infectious disease diagnostics, IVD products, molecular biology, cell immunology, immunoassay, bioassays, MicroRNA profiling, research reagents, health warning products